Cargando…

PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

INTRODUCTION: In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer. METHODS: Tumor DNA from 140 patients with stage II–III breast cancer undergoing neoadjuvant chemotherapy wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Liedtke, Cornelia, Cardone, Luca, Tordai, Attila, Yan, Kai, Gomez, Henry L, Figureoa, Luis J Barajas, Hubbard, Rebekah E, Valero, Vicente, Souchon, Eduardo A, Symmans, W Fraser, Hortobagyi, Gabriel N, Bardelli, Alberto, Pusztai, Lajos
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2397526/
https://www.ncbi.nlm.nih.gov/pubmed/18371219
http://dx.doi.org/10.1186/bcr1984
_version_ 1782155636015890432
author Liedtke, Cornelia
Cardone, Luca
Tordai, Attila
Yan, Kai
Gomez, Henry L
Figureoa, Luis J Barajas
Hubbard, Rebekah E
Valero, Vicente
Souchon, Eduardo A
Symmans, W Fraser
Hortobagyi, Gabriel N
Bardelli, Alberto
Pusztai, Lajos
author_facet Liedtke, Cornelia
Cardone, Luca
Tordai, Attila
Yan, Kai
Gomez, Henry L
Figureoa, Luis J Barajas
Hubbard, Rebekah E
Valero, Vicente
Souchon, Eduardo A
Symmans, W Fraser
Hortobagyi, Gabriel N
Bardelli, Alberto
Pusztai, Lajos
author_sort Liedtke, Cornelia
collection PubMed
description INTRODUCTION: In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer. METHODS: Tumor DNA from 140 patients with stage II–III breast cancer undergoing neoadjuvant chemotherapy was sequenced for PIK3CA mutations on exons 1, 9, and 20. Mutation status was correlated with clinical/pathological parameters and chemotherapy response as (a) pathological complete response (pCR) versus residual cancer or (b) quantitative residual cancer burden (RCB) scores, including stratification for estrogen receptor (ER) expression status, type of chemotherapy, and by exons. RESULTS: Twenty-three patients (16.4%) harbored a PIK3CA mutation, with 12, 11, and 0 mutations located in exons 9, 20, and 1, respectively. PIK3CA exon 9 mutations were more frequent among node-negative (52% versus 25%; P = 0.012) than node-positive tumors, particularly among ER-positive tumors. pCR rates and RCB scores were similar among patients with the wild-type and mutant PIK3CA genes, even after stratification by ER status, chemotherapy regimen (anthracycline versus anthracycline plus paclitaxel), or exon. CONCLUSION: PIK3CA mutations are not associated with altered sensitivity to preoperative anthracycline-based or taxane-based chemotherapies in ER-positive and ER-negative breast tumors. In this study, PIK3CA mutation was associated with a decreased rate of node-positive disease, particularly among ER-positive tumors.
format Text
id pubmed-2397526
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23975262008-05-30 PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer Liedtke, Cornelia Cardone, Luca Tordai, Attila Yan, Kai Gomez, Henry L Figureoa, Luis J Barajas Hubbard, Rebekah E Valero, Vicente Souchon, Eduardo A Symmans, W Fraser Hortobagyi, Gabriel N Bardelli, Alberto Pusztai, Lajos Breast Cancer Res Research Article INTRODUCTION: In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer. METHODS: Tumor DNA from 140 patients with stage II–III breast cancer undergoing neoadjuvant chemotherapy was sequenced for PIK3CA mutations on exons 1, 9, and 20. Mutation status was correlated with clinical/pathological parameters and chemotherapy response as (a) pathological complete response (pCR) versus residual cancer or (b) quantitative residual cancer burden (RCB) scores, including stratification for estrogen receptor (ER) expression status, type of chemotherapy, and by exons. RESULTS: Twenty-three patients (16.4%) harbored a PIK3CA mutation, with 12, 11, and 0 mutations located in exons 9, 20, and 1, respectively. PIK3CA exon 9 mutations were more frequent among node-negative (52% versus 25%; P = 0.012) than node-positive tumors, particularly among ER-positive tumors. pCR rates and RCB scores were similar among patients with the wild-type and mutant PIK3CA genes, even after stratification by ER status, chemotherapy regimen (anthracycline versus anthracycline plus paclitaxel), or exon. CONCLUSION: PIK3CA mutations are not associated with altered sensitivity to preoperative anthracycline-based or taxane-based chemotherapies in ER-positive and ER-negative breast tumors. In this study, PIK3CA mutation was associated with a decreased rate of node-positive disease, particularly among ER-positive tumors. BioMed Central 2008 2008-03-27 /pmc/articles/PMC2397526/ /pubmed/18371219 http://dx.doi.org/10.1186/bcr1984 Text en Copyright © 2008 Liedtke et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liedtke, Cornelia
Cardone, Luca
Tordai, Attila
Yan, Kai
Gomez, Henry L
Figureoa, Luis J Barajas
Hubbard, Rebekah E
Valero, Vicente
Souchon, Eduardo A
Symmans, W Fraser
Hortobagyi, Gabriel N
Bardelli, Alberto
Pusztai, Lajos
PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
title PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
title_full PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
title_fullStr PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
title_full_unstemmed PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
title_short PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer
title_sort pik3ca-activating mutations and chemotherapy sensitivity in stage ii–iii breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2397526/
https://www.ncbi.nlm.nih.gov/pubmed/18371219
http://dx.doi.org/10.1186/bcr1984
work_keys_str_mv AT liedtkecornelia pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT cardoneluca pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT tordaiattila pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT yankai pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT gomezhenryl pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT figureoaluisjbarajas pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT hubbardrebekahe pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT valerovicente pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT souchoneduardoa pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT symmanswfraser pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT hortobagyigabrieln pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT bardellialberto pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer
AT pusztailajos pik3caactivatingmutationsandchemotherapysensitivityinstageiiiiibreastcancer